Matthew Lumley
Chief Executive Officer at Myosana Therapeutics, Inc.
Network origin in Matthew Lumley first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Imperial College London
161
| College/University | Other Consumer Services | 161 |
King's College London
58
| College/University | Other Consumer Services | 58 |
Medicxi Ventures (Jersey) Ltd.
 Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.
22
| Private Company | Investment Managers | 22 |
Myosana Therapeutics, Inc.
 Myosana Therapeutics, Inc. BiotechnologyHealth Technology Myosana Therapeutics, Inc. is a biotech company develops novel platform technology. The company was founded by Stan Froehner, Nick Whitehead and Steve Runnels and is headquartered in Seattle, WA.
3
| Holding Company | Biotechnology | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Matthew Lumley via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| COMPUGEN LTD. | Biotechnology | Chairman Director/Board Member | |
| AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| IPSEN | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NormOxys, Inc.
 NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| RENCO HOLDINGS GROUP LIMITED | Electronic Components | Director/Board Member | |
| University of Oxford | College/University | Graduate Degree Doctorate Degree | |
Index Ventures SA
 Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Investment Managers | Founder Private Equity Analyst Private Equity Analyst Private Equity Analyst | |
| The University of Manchester | College/University | Undergraduate Degree Graduate Degree | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| Trinity College Dublin | College/University | Undergraduate Degree | |
| University of Birmingham | College/University | Undergraduate Degree Doctorate Degree | |
| London School of Economics & Political Science | College/University | Graduate Degree Graduate Degree | |
| University College London | College/University | Doctorate Degree Graduate Degree | |
| University of Bocconi | College/University | Undergraduate Degree Graduate Degree | |
| London Business School | College/University | Masters Business Admin Undergraduate Degree | |
| Bayes Business School | College/University | Corporate Officer/Principal Graduate Degree Masters Business Admin | |
Polus Capital Management Ltd.
 Polus Capital Management Ltd. Investment ManagersFinance Polus Capital Management Ltd. (Polus) is an alternative investment management firm headquartered in London, UK. The firm was founded in 2004 and formerly known as Cairn Financial Products Ltd. and as Cairn Capital Ltd. They are a subsidiary of Cairn Capital Group Ltd., which is owned by Mediobanca Banca di Credito Finanziario SpA (BIT: MB) in Italy. Polus provides bespoke, innovative investment solutions to institutional investors which include public pensions, corporate pensions, endowments, foundations, insurance companies and family offices. The firm is a signatory of several industry initiatives such as the PRI, SBAI and UNGC. | Investment Managers | Portfolio Manager-Fixed Income | |
Atomico (UK) Partners LLP
 Atomico (UK) Partners LLP Investment ManagersFinance Atomico (UK) Partners LLP (Atomico (UK) Partners) is a venture capital firm founded in 2006 by Mattias Ljungman and Niklas Mårten Zennström. The firm is headquartered in London, United Kinghdom with additional offices in Sau Paulo and New York. | Investment Managers | Private Equity Analyst Private Equity Analyst | |
| MOLECULAR PARTNERS AG | Biotechnology | Director/Board Member Director/Board Member | |
Stealthyx Therapeutics Ltd.
 Stealthyx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Stealthyx Therapeutics Ltd. operates drug delivery system technology. The company was founded by Yuti Chernajovsky and Eileen Janis Anderson in 2002 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman | |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
| Index Ventures (UK) LLP | Investment Managers | Private Equity Investor Private Equity Investor | |
Deloitte LLP (United Kingdom)
 Deloitte LLP (United Kingdom) Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Deloitte LLP (United Kingdom) provides brokerage services. The company is based in London, UK. David Sproul has been the CEO of the British company since 2003. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Epsilon-3 Bio Ltd
 Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
XO1 Ltd.
 XO1 Ltd. Medical/Nursing ServicesHealth Services XO1 Ltd. develops a novel anticoagulant drug. The firm operates as a biopharmaceutical company. The company was founded by David J. Grainger on February 28, 2013 and is headquartered in High Wycombe, the United Kingdom. | Medical/Nursing Services | Founder Founder | |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Private Equity Investor | |
| MINERVA NEUROSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Levicept Ltd.
 Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Generic | Chairman Director/Board Member Director/Board Member | |
| Stx Pharma Ltd. | Director/Board Member Founder | ||
Morphogen-IX Ltd.
 Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Founder | |
| Royal College of Science | College/University | Corporate Officer/Principal | |
Gadeta BV
 Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Medical Specialties | Director/Board Member Director/Board Member | |
Inhibitaxin Ltd.
 Inhibitaxin Ltd. BiotechnologyHealth Technology Inhibitaxin Ltd. engages in research and development on biotechnology. The company was founded by Simon Lempriere Westbrook and Kevin S. Johnson in 2013 and is headquartered in Kent, the United Kingodm. | Biotechnology | Founder Director/Board Member | |
Janpix Holdings, Inc.
 Janpix Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Janpix Holdings, Inc. engages in provision of research and experimental development on biotechnology. The company was founded by Patrick T. Gunning and Cortes Pierre and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Z Factor Ltd.
 Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
ApcinteX Ltd.
 ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Founder | |
Palladio Biosciences, Inc.
 Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | Biotechnology | Director/Board Member Director/Board Member | |
UltraHuman Ltd.
 UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Critical Pressure Ltd.
 Critical Pressure Ltd. Pharmaceuticals: MajorHealth Technology Critical Pressure Ltd. engages in research and experimental development on biotechnology. The firm develops products to treat vascular dysfunction and shock. The company is headquartered in Babraham, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Rebalance (Cambridge) Ltd.
 Rebalance (Cambridge) Ltd. Miscellaneous Commercial ServicesCommercial Services Rebalance (Cambridge) Ltd. provides research and experimental development on biotechnology. The company was founded on December 6, 2016 and is headquartered in Hatfield, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Human Antibody Factory Ltd.
 Human Antibody Factory Ltd. BiotechnologyHealth Technology Human Antibody Factory Ltd. provides research and experimental development on biotechnology. The company was founded by David John Grainger and is headquartered in Hatfield, the United Kingdom. | Biotechnology | Director/Board Member Founder | |
| Kaerus Bioscience Ltd. | Chairman Director/Board Member | ||
| CENTESSA PHARMACEUTICALS PLC | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
SDS Therapeutics Ltd.
 SDS Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member |
Statistics
International
| United Kingdom | 33 |
| United States | 9 |
| Netherlands | 4 |
| Switzerland | 3 |
| Israel | 2 |
Sectoral
| Health Technology | 24 |
| Consumer Services | 12 |
| Commercial Services | 8 |
| Finance | 6 |
| Electronic Technology | 2 |
Operational
| Director/Board Member | 302 |
| Corporate Officer/Principal | 114 |
| Undergraduate Degree | 72 |
| Founder | 60 |
| Private Equity Investor | 53 |
Most connected contacts
| Insiders | |
|---|---|
| Paul Sekhri | 62 |
| Wen Hong Lum | 44 |
| Michèle Ollier | 40 |
| Francesco de Rubertis | 36 |
| David Grainger | 29 |
| Giuseppe Zocco | 26 |
| Sanford Zweifach | 22 |
| Kevin Johnson | 22 |
| Lord Darzi | 18 |
| Yi Ke Guo | 16 |
| Alasdair Thong | 15 |
| Luisa Moreno | 15 |
| Imran Hamid | 14 |
| Christopher Kelly | 12 |
| Giovanni Mariggi | 11 |
- Stock Market
- Insiders
- Matthew Lumley
- Company connections
